Mechanism of action of amylin in bone

Amylin is a 37 amino acid peptide produced mainly by β‐cells of the endocrine pancreas. Human amylin has 43% homology with human calcitonin gene‐related peptide (CGRP) and 13% homology with human calcitonin (CT). Amylin and CGRP have been reported to have CT‐like hypocalcemic activity in vivo. To investigate the role of amylin in bone, we examined the mechanisms of action of human amylin, CGRP, and CT in osteoclasts and osteoblasts. Both human amylin and CGRP inhibited 1α, 25‐dihydroxyvitamin D3 [1α, 25(OH)2D3]‐induced bone resorption in an organ culture system, and the potencies of the two peptides were similarly ∼60‐fold lower than that of human CT. Using a recently developed procedure for preparing large numbers of osteoclast‐like multinucleated cells (MNCs) formed in co‐cultures of mouse osteoblasts and bone marrow cells in the presence of 1α, 25(OH)2D3, we found that both human amylin and CGRP stimulated cAMP production in osteoclast‐like MNCs, but only at 60‐fold higher concentrations than human CT. Specific binding of [125I]‐human CT to osteoclast‐like MNCs was detected (dissociation constant, 3 × 10−8 M; binding sites, 3 × 107 per cell). To displace the bound [125I]‐human CT from osteoclast‐like MNCs, about 170‐fold higher concentrations of human amylin and CGRP were required. No specific bindings of [125I]‐CGRP to osteoclast‐like MNCs could be detected. Human CGRP stimulated cAMP production both in established mouse osteoblast‐like cells (KS‐4) and in mouse primary osteoblast‐like cells. Amylin was a weak agonist for cAMP production in KS‐4 cells. The increment in cAMP production induced by CGRP and amylin was abolished by the addition of human CGRP(8–37), a selective antagonist for CGRP receptors. CT did not stimulate cAMP production in KS‐4 cells. Amylin, but not CT, displaced the bound [125I]‐human CGRP from rat brain membranes. These results indicate that amylin binds not only to CT receptors in osteoclast‐like MNCs but also to CGRP receptors in osteoblasts. The relative potencies of these compounds to induce cAMP production was CT > amylin ≒ CGRP in osteoclast‐like MNCs and CGRP > amylin ≫ CT in osteoblast‐like cells. © 1992 Wiley‐Liss, Inc.

[1]  H. Lodish,et al.  Expression cloning of an adenylate cyclase-coupled calcitonin receptor. , 1991, Science.

[2]  T. Martin,et al.  Structure‐activity relationships in calcitonin gene‐related peptide: Cyclic AMP response in a preosteoblast cell line (ks‐4) , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  M. Zaidi,et al.  Selective antagonism of calcitonin-induced osteoclastic quiescence (Q effect) by human calcitonin gene-related peptide-(Val8Phe37). , 1991, Biochemical and biophysical research communications.

[4]  S. Gardiner,et al.  Antagonistic Effect of Human α-Calcitonin Gene–Related Peptide (8–37) on Regional Hemodynamic Actions of Rat Islet Amyloid Polypeptide in Conscious Long-Evans Rats , 1991, Diabetes.

[5]  A. Saltiel,et al.  Amylin increases cyclic AMP formation in L6 myocytes through calcitonin gene-related peptide receptors. , 1991, Biochemical and biophysical research communications.

[6]  R. Fisher,et al.  Characterization and regulation of high affinity calcitonin gene-related peptide receptors in cultured neonatal rat cardiac myocytes. , 1991, Endocrinology.

[7]  N. Udagawa,et al.  Role of prostaglandins in interleukin‐1‐induced bone resorption in mice in vitro , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  N. Udagawa,et al.  Cloning of an osteoblastic cell line involved in the formation of osteoclast‐like cells , 1990, Journal of cellular physiology.

[9]  S. Gardiner,et al.  Antagonistic effect of human α-CGRP [8–37] on the in vivo regional haemodynamic actions of human α-CGRP , 1990 .

[10]  H. Datta,et al.  Evidence that the action of calcitonin on rat osteoclasts is mediated by two G proteins acting via separate post-receptor pathways. , 1990, The Journal of endocrinology.

[11]  H. Datta,et al.  Amylin‐amide: a new bone‐conserving peptide from the pancreas , 1990, Experimental physiology.

[12]  R. Epand,et al.  Evidence for calcitonin receptor heterogeneity: binding studies with nonhelical analogs. , 1990, Endocrinology.

[13]  D. Steiner,et al.  Islet amyloid polypeptide. A new beta cell secretory product related to islet amyloid deposits. , 1990, The Journal of biological chemistry.

[14]  T. Martin,et al.  The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. , 1989, Endocrinology.

[15]  H. Datta,et al.  In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit. , 1989, Biochemical and biophysical research communications.

[16]  S. Bloom,et al.  Expression of the rat amylin (IAPP/DAP) gene. , 1989, Journal of molecular endocrinology.

[17]  C. Newgard,et al.  Rat amylin: cloning and tissue-specific expression in pancreatic islets. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Makino,et al.  Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. , 1989, Biochemical and biophysical research communications.

[19]  T. Martin,et al.  Effects of calcitonin gene‐related peptide on cyclic AMP formation in chicken, rat, and mouse bone cells , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  G. Cooper,et al.  Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro , 1988, Nature.

[21]  J. Rothbard,et al.  Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Schultzberg,et al.  Substance P- and CGRP-immunoreactive nerves in bone , 1988, Peptides.

[23]  R. Turner,et al.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Wernstedt,et al.  A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. , 1986, Biochemical and biophysical research communications.

[25]  P. Sexton,et al.  Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. , 1986, The Journal of clinical investigation.

[26]  K. Kasono,et al.  Stimulation of prostaglandin E2 and bone resorption by recombinant human interleukin 1 alpha in fetal mouse bones. , 1986, Biochemical and biophysical research communications.

[27]  G. Mundy,et al.  Human synthetic calcitonin gene-related peptide inhibits bone resorption in vitro. , 1986, Endocrinology.

[28]  H. Morris,et al.  The myotropic and plasma-calcium modulating effects of calcitonin gene-related peptide (CGRP) , 1984, Neuropeptides.

[29]  H. Nakamuta,et al.  Binding sites of calcitonin gene-related peptide (CGRP): abundant occurrence in visceral organs. , 1986, Japanese journal of pharmacology.

[30]  L. Raisz BONE RESORPTION IN TISSUE CULTURE. FACTORS INFLUENCING THE RESPONSE TO PARATHYROID HORMONE. , 1965, The Journal of clinical investigation.